Invion Limited

A clinical-stage drug development company focused on the development of treatments for major market opportunities in inflammatory diseases including asthma, chronic bronchitis and lupus. Hear CMO Dr Mitchell Glass discuss the results of Invion's successful P2 clinical trial in smoking cessation.

Invion Limited

Invion has three drug assets in development across four development programs. Two phase II clinical trials have reported data in 2015, and Invion has submitted an FDA EOP2 request for its smoking cessation program. Read more in the latest corporate presentation.